10x Genomics (TXG) Income from Continuing Operations (2018 - 2026)

10x Genomics (TXG) has 9 years of Income from Continuing Operations data on file, last reported at 13470000.0 in Q1 2026.

• For the quarter ending Q1 2026, Income from Continuing Operations rose 60.8% year-over-year to 13470000.0; the trailing twelve-month figure through Mar 2026 stood at 22656000.0 (up 85.57% YoY), and the FY2025 full-year result was 43544000.0, up 76.16% from the prior year.
• Income from Continuing Operations climbed to 13470000.0 in Q1 2026, from 16252000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 34538000.0 in Q2 2025 to a low of 92986000.0 in Q3 2023.
• A 5-year average of 38867058.82 and a median of 41914000.0 in 2022 frame the typical range for Income from Continuing Operations.
• Across the five-year window, Income from Continuing Operations tumbled 483.22% in 2022 and surged 191.14% in 2025, its largest moves.
• Tracing TXG's Income from Continuing Operations over 5 years: stood at 17215000.0 in 2022, then plunged by 184.36% to 48952000.0 in 2023, then slipped by 0.16% to 49028000.0 in 2024, then jumped by 66.85% to 16252000.0 in 2025, then increased by 17.12% to 13470000.0 in 2026.
• Business Quant data shows TXG's Income from Continuing Operations at 13470000.0 in Q1 2026, 16252000.0 in Q4 2025, and 27472000.0 in Q3 2025.